Scalper1 News
Biotech Achillion Pharmaceuticals (ACHN) got another boost Monday when Maxim Group more than tripled its price target on the stock, sending shares up 17% in morning trading on the stock market today. After having dinner with company executives, analyst Jason Kolbert hiked his target to 22 from 6, while maintaining his buy rating. He cited the potential of all three of Achillion’s hepatitis C drug candidates, with the ultimate goal of creating a Scalper1 News
Scalper1 News